MedTrace Logo

MK0476 Study in Adult Patients With Allergic Rhinitis (0476-378)

NCT00446186 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 945

Last updated 2024-08-15

No results posted yet for this study

Summary

The clinical study evaluates the efficacy and safety of MK0476 in adult patients with allergic rhinitis.

Conditions

  • Rhinitis Allergic

Interventions

DRUG

MK0476, montelukast sodium / Duration of Treatment: 2 Weeks

DRUG

Comparator: placebo / Duration of Treatment: 2 Weeks

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-02-29
Primary Completion
2004-03-31
Completion
2004-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00446186 on ClinicalTrials.gov